MedTrace Logo

Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)

NCT00886977 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2010-10-25

No results posted yet for this study

Summary

The efficacy and safety are evaluated when YAM80 is administered orally to the patients of Amyotrophic Lateral Sclerosis (ALS).

Conditions

Interventions

DRUG

YAM80

Oral administration, 2 to 6 mg, once a day.

Sponsors & Collaborators

  • Yoshino Neurology Clinic

    lead OTHER

Principal Investigators

  • Hiide Yoshino, M.D. · Yoshino Neurology Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886977 on ClinicalTrials.gov